면역치료제 시장 : 약물 종류별, 용도별, 투여 경로별, 유통 채널별 - 세계 예측

Global Immunotherapy Drugs Market will witness 10.4% CAGR between 2024 and 2032, influenced by rising grants and permissions from leading pharmaceutical companies. These financial investments and regulatory approvals are accelerating the development and availability of innovative immunotherapy treatments. Grants from government bodies and private organizations are facilitating advanced research, enabling companies to explore new therapeutic targets and refine treatment protocols. Concurrently, regulatory agencies are increasingly fast-tracking approvals for promising immunotherapy drugs, recognizing their potential to revolutionize cancer treatment and other autoimmune disorders.

For instance, in July 2022, the U.S. Food and Drug Administration (FDA) extended the orphan drug designation for SurVaxM, an immunotherapy for brain cancer developed at Roswell Park Comprehensive Cancer Center.

These supportive measures are enhancing clinical trial opportunities and expediting market entry for novel therapies. As leading companies secure more grants and navigate regulatory landscapes successfully, the pipeline for immunotherapy drugs expands, meeting the growing demand for effective, targeted treatments. This synergy between financial support and regulatory facilitation is driving market growth, positioning immunotherapy as a pivotal component in the future of medical treatments.

The overall Immunotherapy Drugs Industry is classified based on the drug type, application, route of administration, distribution channel, and region.

Based on drug type, the immunotherapy drugs market revenue from the vaccines segment will register a commendable CAGR from 2024 to 2032. These vaccines, designed to stimulate the immune system to target and destroy cancer cells, represent a significant leap forward in personalized medicine. With ongoing research and clinical trials demonstrating their potential to enhance treatment efficacy and patient outcomes, cancer vaccines are gaining traction. The growing focus on immunotherapy as a viable treatment option, combined with the push for preventive measures and personalized approaches, is fueling market growth. As pharmaceutical companies invest in developing and commercializing these innovative vaccines, the demand for immunotherapy drugs will rise substantially.

In terms of application, the auto immune diseases segment will witness appreciable growth from 2024 to 2032. These drugs, which harness the body's immune system to target and modify disease mechanisms, offer new hope for conditions like rheumatoid arthritis, multiple sclerosis, and lupus. As research uncovers more about the immune system's role in these disorders, immunotherapies are becoming increasingly effective in managing symptoms and altering disease progression. The growing prevalence of autoimmune diseases and the need for targeted, personalized treatments drive market growth. Investments in research and development are further accelerating the availability of novel immunotherapies, enhancing patient outcomes, and fueling market expansion.

Europe immunotherapy drugs market will exhibit a notable CAGR from 2024 to 2032. European countries are increasingly adopting immunotherapies due to their promising results in targeting specific cancer cells and improving patient outcomes. The European Union's supportive regulatory environment and funding initiatives for innovative therapies further bolster this demand. In addition, rising awareness among patients and healthcare providers about the benefits of immunotherapy fuels market expansion. As European pharmaceutical companies invest in research and development and collaborate on clinical trials, the demand for cutting-edge immunotherapy drugs could continue its upward trajectory.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Growing adoption of combination therapies
    • 3.2.1.3 Technological advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Monoclonal antibodies
• 5.3 Vaccines
• 5.4 Check point inhibitor
• 5.5 Interferons alpha & beta
• 5.6 Interleukins
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
• 6.3 Autoimmune diseases
• 6.4 Infectious diseases
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Intravenous
• 7.3 Subcutaneous
• 7.4 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Brick and mortar
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca
• 10.4 Bayer AG
• 10.5 Boehringer Ingelheim
• 10.6 Eli Lilly and Company
• 10.7 F. Hoffmann-La Roche Ltd.
• 10.8 Genmab A/S
• 10.9 GSK plc
• 10.10 Immatics N.V.
• 10.11 Johnson & Johnson Services, Inc.
• 10.12 Merck & Co., Inc.
• 10.13 Novartis AG
• 10.14 Pfizer, Inc.
• 10.15 Sanofi